SOUTH SAN FRANCISCO, Calif.,
Jan. 5, 2022 /PRNewswire/
-- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic
lethality focused precision medicine oncology company committed to
the discovery and development of targeted therapeutics, reported
the acquisition of its INQUIRE™ Chemical Library to enhance the
company's synthetic lethality drug discovery platform.
IDEAYA's INQUIRE Chemical Library is a proprietary,
expert-curated small-molecule library of over 200,000 chemical
compounds. The collection includes compounds selected for
lead-like properties and molecular diversity, including novel sp3
enriched chemotypes, a-helix and b-sheet mimetics and privileged
structures. IDEAYA believes this will enhance its hit discovery
capabilities across a broad range of novel synthetic lethality
targets and historically difficult-to-drug target classes, such as
helicases and endonucleases.
"The INQUIRE Chemical Library represents another important
building block in our synthetic lethality drug discovery platform,
where we have continued to expand IDEAYA's drug discovery
capabilities, including in structural biology, structure-based drug
design, and protein degrader chemistry. We have developed
substantial know-how in synthetic lethality drug discovery, and we
believe this proprietary chemical library enhances our existing
hit-finding capabilities to discover novel chemical entities which
are active and selective against novel synthetic lethality
targets," said Michael White, Ph.D.,
Senior Vice President and Chief Scientific Officer of IDEAYA
Biosciences.
IDEAYA is a leading synthetic lethality focused biotechnology
company with capabilities for identifying and validating synthetic
lethality targets and biomarkers. The company applies drug
discovery capabilities against validated synthetic lethality
targets which could be impactful to patients with a specific
patient selection biomarker. IDEAYA has integrated multiple
drug discovery technologies and capabilities, including hit
discovery, structural biology, computational chemistry, and
analytical chemistry, among other core functional
expertise.
IDEAYA has advanced multiple potential first-in-class Synthetic
Lethality programs through its internal drug discovery platform,
including IDE397, a Phase 1 MAT2A inhibitor, PARG, Pol Theta, and
Werner Helicase. IDEAYA has achieved significant drug
discovery milestones across each of these programs, including the
identification of novel chemical matter, resolving key co-crystal
structures that enable structure-based lead optimization, and the
discovery of multiple potential first-in-class and best-in-class
development candidates. IDEAYA has a broad next generation
synthetic lethality portfolio, including two undisclosed programs
in lead optimization that are structurally enabled, a
first-in-class target undergoing hit identification, and multiple
additional novel targets undergoing target and biomarker
validation.
About IDEAYA Biosciences
IDEAYA is a synthetic lethality focused precision medicine
oncology company committed to the discovery and development of
targeted therapeutics for patient populations selected using
molecular diagnostics. IDEAYAs approach integrates
capabilities in identifying and validating translational biomarkers
with drug discovery to select patient populations most likely to
benefit from its targeted therapies. IDEAYA is applying its
research and drug discovery capabilities to synthetic lethality –
which represents an emerging class of precision medicine targets.
Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to, statements related to (i) the
enhancement of IDEAYA's hit discovery capabilities and (ii) the
potential first-in-class nature of its programs. Such
forward-looking statements involve substantial risks and
uncertainties that could cause IDEAYA's preclinical and clinical
development programs, future results, performance or achievements
to differ significantly from those expressed or implied by the
forward-looking statements. Such risks and uncertainties include,
among others, the uncertainties inherent in the drug development
process, including IDEAYA's programs' early stage of development,
the process of designing and conducting preclinical and clinical
trials, the regulatory approval processes, the timing of regulatory
filings, the challenges associated with manufacturing drug
products, IDEAYA's ability to successfully establish, protect and
defend its intellectual property, the effects on IDEAYA's business
of the worldwide COVID-19 pandemic, and other matters that could
affect the sufficiency of existing cash to fund operations. IDEAYA
undertakes no obligation to update or revise any forward-looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of IDEAYA in general, see IDEAYA's recent
Quarterly Report on Form 10-Q filed on November 15, 2021 and any current and periodic
reports filed with the U.S. Securities and Exchange Commission.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-acquisition-of-proprietary-inquire-chemical-library-to-enhance-synthetic-lethality-drug-discovery-platform-301452407.html
SOURCE IDEAYA Biosciences, Inc.